Healthcare provider profile · identity verified

Tri V. Tran, MD

Family Practice · ANAHEIM, CA · NPI 1649342981

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	942	313
Lisinopril	Lisinopril	386	132
Losartan Potassium	Losartan Potassium	369	125
Amlodipine Besylate	Amlodipine Besylate	251	83
Levothyroxine Sodium	Levothyroxine Sodium	243	75
Atenolol	Atenolol	223	70
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	216	32
Simvastatin	Simvastatin	198	60
Hydrochlorothiazide	Hydrochlorothiazide	194	63
Meloxicam	Meloxicam	183	96
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	164	51
Azelastine Hcl	Azelastine Hcl	162	70
Alendronate Sodium	Alendronate Sodium	159	50
Metformin Hcl	Metformin Hcl	152	47
Tamsulosin Hcl	Tamsulosin Hcl	149	52
Metformin Hcl Er	Metformin Hcl	145	52
Rosuvastatin Calcium	Rosuvastatin Calcium	141	51
Prednisone	Prednisone	140	111
Metoprolol Tartrate	Metoprolol Tartrate	137	49
Omeprazole	Omeprazole	130	51
Pantoprazole Sodium	Pantoprazole Sodium	130	38
Potassium Chloride	Potassium Chloride	126	44
Jardiance	Empagliflozin	125	44
Glipizide	Glipizide	120	40
Albuterol Sulfate Hfa	Albuterol Sulfate	114	59
Terazosin Hcl	Terazosin Hcl	100	25
Trazodone Hcl	Trazodone Hcl	95	25
Allopurinol	Allopurinol	92	32
Pradaxa	Dabigatran Etexilate Mesylate	89	23
Ipratropium Bromide	Ipratropium Bromide	82	54
Finasteride	Finasteride	80	26
Clopidogrel	Clopidogrel Bisulfate	78	26
Fluocinonide	Fluocinonide	71	39
Tramadol Hcl	Tramadol Hcl	70	22
Azithromycin	Azithromycin	67	63
Furosemide	Furosemide	65	21
Gabapentin	Gabapentin	65	21
Triamcinolone Acetonide	Triamcinolone Acetonide	65	36
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	62	22
Lorazepam	Lorazepam	52	12
Ezetimibe	Ezetimibe	51	17
Glipizide-Metformin	Glipizide/Metformin Hcl	50	18
Ibuprofen	Ibuprofen	50	20
Glipizide Er	Glipizide	45	16
Clobetasol Propionate	Clobetasol Propionate	44	24
Humulin N	Insulin Nph Human Isophane	42	12
Ozempic	Semaglutide	41	suppressed
Alprazolam	Alprazolam	39	suppressed
Sertraline Hcl	Sertraline Hcl	38	16
Temazepam	Temazepam	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	32	11
Spironolactone	Spironolactone	32	11
Cephalexin	Cephalexin	31	28
Mirtazapine	Mirtazapine	30	11
Sumatriptan Succinate	Sumatriptan Succinate	30	suppressed
Famotidine	Famotidine	29	12
Pioglitazone Hcl	Pioglitazone Hcl	29	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	29	13
Amoxicillin	Amoxicillin	28	suppressed
Humulin R	Insulin Regular, Human	28	suppressed
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Nystatin	Nystatin	27	20
Buspirone Hcl	Buspirone Hcl	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Myrbetriq	Mirabegron	24	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	24	19
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	24	suppressed
Trospium Chloride	Trospium Chloride	23	suppressed
Alvesco	Ciclesonide	22	12
Ciclopirox	Ciclopirox	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Tacrolimus	Tacrolimus	22	16
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	21
Eliquis	Apixaban	21	suppressed
Ibandronate Sodium	Ibandronate Sodium	21	suppressed
Metoprolol Succinate	Metoprolol Succinate	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Clindamycin Hcl	Clindamycin Hcl	16	15
Doxycycline Monohydrate	Doxycycline Monohydrate	16	15
Estradiol	Estradiol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Metronidazole	Metronidazole	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Retin-A	Tretinoin	16	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	15	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Sulindac	Sulindac	14	suppressed
Testosterone	Testosterone	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Clindamycin Phosphate	Clindamycin Phosphate	12	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	11	11
Latanoprost	Latanoprost	11	suppressed
Naproxen	Naproxen	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error